C2Dx Announces FDA Clearance for Advanced Shaw Scalpel System

On March 26, 2024, C2Dx, a medical device company based in Kalamazoo, MI, reported receiving 510(k) clearance from the FDA for a new generation of its Shaw Scalpel System. This surgical device is designed to improve the user experience significantly by enabling precise anatomical dissection and providing immediate hemostasis, resulting in a cleaner and drier surgical field. The system aims to enhance the visualization and safety of dissecting nerves and critical anatomy.

Ben Burnham, VP of Sales and Marketing at C2Dx, expressed that this approval signifies a blend of user feedback and team effort, underscoring the technology's safety and efficiency. With over a century of collective experience, the C2Dx team, led by CEO Kevin McLeod, has expanded its product range and capabilities. The partnership with Shore Capital Partners aims to further establish the company's leadership in the medical device sector through acquisitions and organic growth.

Dr. Donald B. Kamerer Jr. has highlighted the next generation Shaw Scalpel System's advantages in surgical precision and efficiency, especially in complex anatomical areas. The device is praised for minimizing blood loss and maintaining visibility during surgeries.

C2Dx is actively seeking to enhance its presence in the medical device industry by exploring new partnerships and expanding its investment in product development and human resources. The company's goal is to serve various medical specialties globally.